T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
AMN Healthcare
AMN
$1.34B
| $98.5M | 0.01% |
805,424
-11,111
| -1% | -$1.23M |
|
|
UNVR
777
DELISTED
Univar Solutions Inc.
UNVR
| $97.9M | 0.01% |
3,454,736
-71,820
| -2% | -$1.94M |
|
778
Columbia Banking Systems
COLB
$9.18B
| $97.5M | 0.01% |
2,981,055
-234,980
| -7% | -$8.14M |
|
779
Builders FirstSource
BLDR
$7.91B
| $97.4M | 0.01% |
1,136,445
-16,196
| -1% | -$1.1M |
|
780
Dime Commercial Bancshares
DCOM
$1.82B
| $96.4M | 0.01% |
2,742,599
-34,360
| -1% | -$1.21M |
|
781
Unity
U
$20.2B
| $95.9M | 0.01% |
670,462
+622,942
| +1,311% | +$95.2M |
|
782
Walker & Dunlop
WD
$1.47B
| $95.8M | 0.01% |
635,167
+6,921
| +1% | +$964K |
|
|
GBT
783
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $95.4M | 0.01% |
3,260,685
-147,309
| -4% | -$4.56M |
|
784
Waters Corp
WAT
$40.6B
| $94.9M | 0.01% |
254,712
+13,951
| +6% | +$4.88M |
|
785
Agios Pharmaceuticals
AGIO
$2B
| $94.6M | 0.01% |
2,878,714
-152,027
| -5% | -$6.12M |
|
|
SAFE
786
DELISTED
Safehold Inc.
SAFE
| $94M | 0.01% |
1,176,743
+12,179
| +1% | +$899K |
|
787
Pennant Group
PNTG
$1.35B
| $93.9M | 0.01% |
4,069,176
-264,951
| -6% | -$6.13M |
|
788
Tandem Diabetes Care
TNDM
$1.61B
| $93.9M | 0.01% |
623,811
-26,494
| -4% | -$3.58M |
|
789
Valmont Industries
VMI
$9.5B
| $93.9M | 0.01% |
374,751
+4,555
| +1% | +$1.12M |
|
790
Winmark
WINA
$1.26B
| $92.4M | 0.01% |
372,324
+323
| +0.1% | +$78.2K |
|
791
Alcoa
AA
$13.1B
| $91.8M | 0.01% |
1,541,082
-65,776
| -4% | -$3.3M |
|
792
Certara
CERT
$1.24B
| $91.3M | 0.01% |
3,214,222
-53,107
| -2% | -$1.79M |
|
793
Paychex
PAYX
$44.6B
| $91.2M | 0.01% |
667,808
-18,148
| -3% | -$2.24M |
|
|
HZNP
794
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $91M | 0.01% |
844,217
-9,974
| -1% | -$1.09M |
|
795
Royalty Pharma
RPRX
$26.1B
| $90.8M | 0.01% |
2,277,559
+80,823
| +4% | +$3.14M |
|
796
Kadant
KAI
$3.91B
| $90.3M | 0.01% |
391,936
-7,449
| -2% | -$1.66M |
|
797
Emerson Electric
EMR
$91.6B
| $90.3M | 0.01% |
970,995
-56,958
| -6% | -$5.36M |
|
|
DFS
798
DELISTED
Discover Financial Services
DFS
| $90.2M | 0.01% |
780,393
-21,408
| -3% | -$2.53M |
|
799
StoneCo
STNE
$2.49B
| $89.8M | 0.01% |
5,326,677
-11,423,031
| -68% | -$290M |
|
800
Iovance Biotherapeutics
IOVA
$2.95B
| $89M | 0.01% |
4,663,785
+39,057
| +0.8% | +$860K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.